Logos Global Management LP decreased its stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 11.4% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 5,150,000 shares of the biopharmaceutical company’s stock after selling 661,436 shares during the quarter. Ocular Therapeutix accounts for about 2.8% of Logos Global Management LP’s investment portfolio, making the stock its 9th largest holding. Logos Global Management LP owned 3.32% of Ocular Therapeutix worth $35,226,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also made changes to their positions in OCUL. Avoro Capital Advisors LLC bought a new stake in shares of Ocular Therapeutix during the 1st quarter worth about $65,055,000. Franklin Resources Inc. acquired a new position in shares of Ocular Therapeutix during the 4th quarter worth about $20,071,000. Vanguard Group Inc. lifted its position in shares of Ocular Therapeutix by 41.4% in the 1st quarter. Vanguard Group Inc. now owns 7,235,131 shares of the biopharmaceutical company’s stock worth $65,840,000 after acquiring an additional 2,117,029 shares during the period. Rosalind Advisors Inc. bought a new stake in shares of Ocular Therapeutix in the 2nd quarter worth approximately $5,130,000. Finally, Great Point Partners LLC bought a new stake in shares of Ocular Therapeutix in the 4th quarter worth approximately $3,122,000. 59.21% of the stock is currently owned by institutional investors and hedge funds.
Ocular Therapeutix Trading Down 5.8 %
NASDAQ OCUL opened at $8.46 on Tuesday. The stock has a 50-day simple moving average of $8.43 and a 200 day simple moving average of $7.41. The company has a market capitalization of $1.31 billion, a PE ratio of -6.27 and a beta of 1.28. The company has a current ratio of 16.64, a quick ratio of 16.55 and a debt-to-equity ratio of 0.18. Ocular Therapeutix, Inc. has a 12 month low of $2.00 and a 12 month high of $11.31.
Wall Street Analyst Weigh In
Several equities analysts recently commented on OCUL shares. Piper Sandler restated an “overweight” rating and set a $15.00 target price on shares of Ocular Therapeutix in a research report on Friday, June 21st. Robert W. Baird dropped their price target on Ocular Therapeutix from $18.00 to $17.00 and set an “outperform” rating for the company in a report on Thursday, August 8th. HC Wainwright restated a “buy” rating and set a $14.00 target price on shares of Ocular Therapeutix in a research report on Thursday, August 1st. Finally, TD Cowen downgraded Ocular Therapeutix from a “strong-buy” rating to a “hold” rating in a research report on Friday, June 21st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $15.67.
View Our Latest Report on Ocular Therapeutix
Ocular Therapeutix Profile
Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
Further Reading
- Five stocks we like better than Ocular Therapeutix
- What is the S&P 500 and How It is Distinct from Other Indexes
- 4 Reasons GlobalFoundries Could Be a Big Winner After Recent Lows
- Insider Buying Explained: What Investors Need to Know
- The Average 401k Balance by Age Explained
- What is a Dividend King?
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
Want to see what other hedge funds are holding OCUL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report).
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.